WebDoctor Encyclopedia

Childhood Soft-tissue sarcomas

CIC-rearranged sarcoma

CIC-rearranged sarcoma is a rare, aggressive soft tissue cancer defined by a CIC gene fusion, usually with DUX4. It mainly affects young adults, often spreads to the lungs and is treated with surgery, radiotherapy and intensive chemotherapy.

Medically reviewed Last reviewed October 20, 2026

What is CIC-rearranged sarcoma?

CIC-rearranged sarcoma is a very rare, aggressive cancer of the soft tissues. It is defined by a specific change in the tumour’s genes: part of the CIC gene on chromosome 19 becomes joined to another gene, most often DUX4. This joining, called a gene fusion, switches on growth signals that drive the cancer. When the partner is DUX4, the tumour is also called CIC::DUX4 sarcoma.

Under the microscope, the tumour is made of small, round blue cells, so it was long thought to be a type of Ewing sarcoma. Doctors used terms such as “Ewing-like sarcoma” or “atypical Ewing sarcoma”. Research then showed that these tumours look, behave and respond to treatment differently. They are now recognised as a separate disease (Antonescu et al., 2017) within a group called undifferentiated small round cell sarcomas.

CIC-rearranged sarcoma usually affects young adults, although children and older adults can also develop it. It typically forms a deep lump in the muscles of the trunk or limbs. It often spreads early, especially to the lungs, and has a poorer outlook than Ewing sarcoma (Makise and Yoshida, 2024).

Treatment combines surgery, radiotherapy and chemotherapy, usually in a specialist sarcoma centre. There is no agreed standard drug treatment, and clinical trials are encouraged (Brahmi et al., 2022).

1. Key facts at a glance

Feature Details
Type of cancer Undifferentiated small round cell sarcoma
Genetic hallmark Fusion of the CIC gene, most often with DUX4
How common Less than 1% of sarcomas
Typical age Young adults; mean about 32 years in a large series
Where it grows Deep soft tissues of the trunk and limbs; rarely organs or bone
Typical spread Lungs, often early
Main treatment Surgery, radiotherapy and intensive chemotherapy
Outlook Poorer than Ewing sarcoma; five-year survival around 40% in one large series

2. Types

Type Description
CIC::DUX4 sarcoma The most common form; DUX4 partner on chromosome 4 or chromosome 10
CIC::FOXO4 and other partners Rare forms with different fusion partners
CIC::NUTM1 sarcoma A rare form, sometimes in the brain or in children

In the large study by Antonescu and colleagues, a CIC::DUX4 fusion was found in 57% of 115 tumours. The rest had CIC rearrangements with partners that could not always be identified.

How it differs from Ewing sarcoma

Feature CIC-rearranged sarcoma Ewing sarcoma
Gene change CIC fusion EWSR1 or FUS fusion with an ETS gene
Usual age Young adults Children and teenagers
Usual site Soft tissue Bone more often
CD99 stain Patchy, often not diffuse Strong and diffuse
WT1 and ETV4 stains Usually positive Usually negative
Response to chemotherapy Often poor Usually good
Five-year survival in matched comparison 43% 77%

The survival comparison comes from a study matching patients by age and stage (Antonescu et al., 2017).

Sarcoma Gene change
Sarcoma with BCOR genetic alterations BCOR fusion or internal duplication
Round cell sarcoma with EWSR1 and non-ETS partners For example EWSR1::NFATC2

3. Causes and risk factors

The cause of CIC-rearranged sarcoma is not known.

Factor Notes
Gene fusion in the tumour Occurs by chance in the tumour cells; not inherited
Age Mostly young adults, but a wide age range
Sex Slightly more common in males
Lifestyle No known link
Previous radiotherapy Not established as a risk factor

The fusion causes ETV4 and related genes to become overactive, driving uncontrolled cell growth (Brahmi et al., 2022). The fusion is present only in the cancer cells, so relatives are not at increased risk.

4. How does it look

Where it grows

Site Share in the Antonescu series
Soft tissue (trunk and limbs) About 86%
Internal organs About 12% (for example kidney, brain, gut)
Bone About 3%

On scans

Test Typical findings
MRI Large, deep soft-tissue mass, often with areas of bleeding or dead tissue
CT of the chest Detects lung spread
PET-CT Shows the extent of disease throughout the body

Under the microscope

Feature Description
Growth pattern Lobules of tumour separated by fibrous bands
Cells Round to oval cells, sometimes spindle-shaped or epithelioid
Nuclei Fairly uniform, with visible nucleoli
Background Patchy myxoid (jelly-like) areas and dead tissue
Helpful stains Nuclear ETV4 and WT1; CD99 often patchy (Makise and Yoshida, 2024)

Confirming the fusion

Method Notes
FISH for CIC Detects a break in the CIC gene
RNA sequencing Identifies the fusion and its partner
Immunostaining for ETV4 A strong supporting clue

Genetic tests can miss CIC::DUX4 fusions, even with modern sequencing. Pathologists therefore combine the appearance, the stains and several tests before making the diagnosis (Makise and Yoshida, 2024).

5. Symptoms

Common symptoms

  • A lump or swelling, often deep in a muscle of the trunk, thigh or arm
  • A lump that grows quickly over weeks
  • Pain in the area, though some lumps are painless

Less common symptoms

Symptom Possible cause
Cough or breathlessness Spread to the lungs
Weight loss, fever, tiredness Advanced disease
Symptoms from an internal organ Tumour in the kidney, gut or brain, for example
Bone pain Spread to bone

When to seek medical advice

See a doctor about any lump that is larger than 5 cm, growing, deep or painful. Most lumps are harmless, but these features warrant an urgent scan and referral to a sarcoma service.

6. Diagnosis

Test Purpose
MRI of the lump Size, depth and relation to nerves and vessels
Core needle biopsy Performed by or in agreement with the sarcoma team, along the future surgical route
Immunostains WT1, ETV4, CD99 and others
Molecular testing Confirms the CIC fusion
CT of the chest Looks for lung spread
PET-CT Full staging
Fertility discussion Before chemotherapy

Staging

Staging uses the TNM system for soft tissue sarcoma, considering size, depth, lymph node involvement and distant spread. Because CIC-rearranged sarcoma is a high-grade tumour, even localised disease is treated intensively.

Group Meaning
Localised Confined to the original site
Advanced Cannot be removed or has spread, usually to the lungs

In an Australian multi-centre series, 11 of 18 patients had localised disease and 7 had advanced disease at diagnosis (Connolly et al., 2022).

7. Treatment

There is no agreed standard treatment. Many centres use an Ewing sarcoma-style approach; others treat it like a high-grade soft tissue sarcoma. Experts recommend combinations of an anthracycline and an alkylating agent where possible, and advise against reducing treatment intensity (Brahmi et al., 2022).

Localised disease

Step Details
Chemotherapy Often given before and after surgery; Ewing-type regimens such as VDC/IE are common
Surgery Removal of the tumour with clear margins
Radiotherapy Before or after surgery to reduce the risk of local recurrence

In the Australian series, most patients with localised disease had complete surgical removal, and most also received radiotherapy and chemotherapy. Even so, more than half later developed metastases, usually within the first year (Connolly et al., 2022).

Chemotherapy regimens

Regimen Drugs
VDC/IE Vincristine, doxorubicin and cyclophosphamide, alternating with ifosfamide and etoposide
VIDE Vincristine, ifosfamide, doxorubicin and etoposide
Doxorubicin with ifosfamide A standard soft tissue sarcoma combination

Advanced disease

Option Notes
Chemotherapy Responses are often short
Surgery or radiotherapy to lung metastases In selected patients
Palliative radiotherapy Controls pain or symptoms
Clinical trials Strongly encouraged, including new targeted approaches

In the Australian series, responses to drug treatment in advanced disease rarely lasted. One patient had a durable complete response to VDC/IE, while single patients given pazopanib or pembrolizumab did not respond (Connolly et al., 2022).

A typical treatment plan for localised disease

Phase What happens Typical length
Diagnosis MRI, biopsy, molecular tests, staging scans 2-4 weeks
Fertility preservation Sperm or egg storage Before chemotherapy starts
Initial chemotherapy Several cycles, often in hospital About 3-4 months
Local treatment Surgery, with radiotherapy before or after 1-2 months
Further chemotherapy Remaining cycles Several months
Rehabilitation Physiotherapy and return to activities Ongoing

Why specialist centres matter

Sarcomas are rare, and CIC-rearranged sarcoma is among the rarest. Specialist teams bring together sarcoma surgeons, oncologists, radiologists and pathologists experienced in molecular diagnosis. Such teams are better placed to confirm the diagnosis, plan surgery that preserves function, and offer access to clinical trials and registries, which experts strongly recommend for this disease (Brahmi et al., 2022).

Side effects

Treatment Possible side effects
Intensive chemotherapy Low blood counts, infections, hair loss, mouth sores, nausea, fatigue
Doxorubicin Heart damage at high cumulative doses
Ifosfamide and cyclophosphamide Bladder irritation, kidney effects, infertility
Surgery Wound problems, loss of function depending on site
Radiotherapy Skin reactions, stiffness, swelling, risk of a second cancer years later

8. Outlook (prognosis)

CIC-rearranged sarcoma has a poor overall prognosis, worse than that of Ewing sarcoma (Makise and Yoshida, 2024).

Group Result
Large series (Antonescu) Five-year overall survival 43%
Localised disease (Connolly) Median survival about 41 months; five-year survival about 34%
Advanced disease (Connolly) Median survival about 13 months
Factor Effect
Localised disease that can be removed Better outlook
Lung metastases at diagnosis Poorer outlook
Complete surgical removal Important for long-term control
Response to chemotherapy Better outlook when the tumour shrinks

Some patients do achieve long-term remission, particularly with localised disease treated in a specialist centre.

9. Follow-up

Time after treatment Typical checks
Years 1-2 Clinic review, MRI of the primary site and chest CT every 2-3 months
Years 3-5 Every 4-6 months
After 5 years Yearly review, including late effects of treatment

Late effects to monitor

Effect Checks
Heart function Echocardiogram after doxorubicin
Kidney function Blood tests after ifosfamide
Fertility and hormones Specialist review
Second cancers Awareness of new lumps or symptoms

10. Living with CIC-rearranged sarcoma

  • Ask to be treated in a specialist sarcoma centre
  • Discuss fertility preservation before chemotherapy
  • Report fever promptly during chemotherapy
  • Work with physiotherapists to keep movement and strength after surgery
  • Ask about clinical trials at diagnosis and if the cancer returns
  • Eat well and stay as active as you can during treatment, with advice from a dietitian if needed
  • Seek emotional support; young adult cancer services and sarcoma charities can help
  • Keep follow-up appointments, as early detection of lung spread can allow treatment

11. Frequently asked questions

Question Answer
Is it Ewing sarcoma? No; it was once thought to be, but it is now a separate disease
Why does the gene test matter? It confirms the diagnosis and separates it from Ewing sarcoma
Is it inherited? No; the gene change is only in the tumour
Why is the treatment so intensive? The cancer is aggressive and often spreads early
Can it be cured? Some people with localised disease are cured, especially after complete removal
Can I exercise during treatment? Gentle activity is usually encouraged; ask your team what is safe
Will I be able to have children? Chemotherapy can affect fertility; ask about sperm or egg storage beforehand
How long does treatment last? Usually most of a year for localised disease
Are there new treatments? Research is under way; clinical trials are the best way to access them

12. Questions to ask your care team

  • Has the CIC fusion been confirmed, and with which partner gene?
  • Has the cancer spread?
  • Which chemotherapy do you recommend, and why?
  • Will I need surgery and radiotherapy?
  • How can I protect my fertility?
  • Are there clinical trials for this sarcoma?
  • What follow-up will I need?
  • Who should I contact if I develop a fever or new symptoms?
  • What support is available for work, study and finances?

Resources

  1. Antonescu, C.R. et al. (2017) ‘Sarcomas with CIC-rearrangements are a distinct pathologic entity with aggressive outcome: a clinicopathologic and molecular study of 115 cases’, American Journal of Surgical Pathology, 41(7), pp. 941-949.
  2. Brahmi, M. et al. (2022) ‘CIC-DUX4 sarcomas’, Current Opinion in Oncology, 34(4), pp. 342-347.
  3. Connolly, E.A. et al. (2022) ‘Systemic treatments and outcomes in CIC-rearranged sarcoma: a national multi-centre clinicopathological series and literature review’, Cancer Medicine, 11(8), pp. 1805-1816.
  4. Makise, N. and Yoshida, A. (2024) ‘CIC-rearranged sarcoma’, Surgical Pathology Clinics, 17(1), pp. 141-151.
  5. National Cancer Institute (2026) Adult Soft Tissue Sarcoma Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/soft-tissue-sarcoma/hp/adult-soft-tissue-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.